SCHEMBL6729901

SCHEMBL6729901

CC1Cc2nc(C(=O)N3CCN(S(=O)(=O)c4cc5ccc(C(=N)N)cc5[nH]4)CC3C(=O)NCc3nnn[nH]3)sc2CN1

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
F10 P00742 13/20 0.41
F2 P00734 7/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733547 0.95 F10 (0.39) F10F2
SCHEMBL6729427 0.93 F10 (0.40) F10F2
SCHEMBL6729420 0.93 F10 (0.40) F10F2
SCHEMBL6732274 0.92 F10 (0.39) F10F2
SCHEMBL6726704 0.92 F10 (0.37) F10F2
SCHEMBL6733611 0.91 F10 (0.48) F10F2
SCHEMBL6729720 0.90 F10 (0.50) F10F2
SCHEMBL6735525 0.90 F10 (0.36) F10F2
SCHEMBL6730404 0.89 F10 (0.39) F10F2
SCHEMBL6730398 0.89 F10 (0.39) F10F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 F10 19/4885F2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.